Clinical

Dataset Information

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva)


ABSTRACT: Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib

DISEASE(S): Non-small Cell Lung Cancer,Colorectal Cancer,Advanced Solid Tumors,Advanced Cancer,Prostate Cancer,Pancreatic Cancer

PROVIDER: 2060049 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR